Prostate-specific antigen and prostate-specific antigen derivatives as predictors of benign prostatic hyperplasia progression

Current Urology Reports

Volumn 8, Issue 4, 2007, Pages 269-274

  Levitt, Jonathan M ^b   Slawin, Kevin M ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; BPH A; DUTASTERIDE; FREE PROSTATE SPECIFIC ANTIGEN; PLACEBO; PRO PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DRUG BLOOD LEVEL; HUMAN; IMMUNOHISTOCHEMISTRY; LOWER URINARY TRACT SYMPTOM; NUCLEAR MAGNETIC RESONANCE IMAGING; PROSTATE CANCER; PROSTATE HYPERTROPHY; REVIEW; SYMPTOM;

BIOLOGICAL MARKERS; DISEASE PROGRESSION; HUMANS; MALE; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; PROTEIN ISOFORMS;

EID: 34547442515     PISSN: 15272737     EISSN: 15346285     Source Type: Journal    
DOI: 10.1007/s11934-007-0072-y     Document Type: Review

References (44)

1. Emberton M, Andriole GL, de la Rosette J, et al.: Benign prostatic hyperplasia: a progressive disease of aging men. Urology 2003, 61:267-273.
2. Jacobsen SJ, Girman CJ, Guess HA, et al.: Natural history of prostatism: longitudinal changes in voiding symptoms in community dwelling men. J Urol 1996, 155:595-600.
3. Arrighi HM, Metter EJ, Guess HA, Fozzard JL: Natural history of benign prostatic hyperplasia and risk of prostatectomy. The Baltimore Longitudinal Study of Aging. Urology 1991, 38:4-8.
4. Roehrborn CG, McConnell J, Bonilla J, et al.: Serum prostate specific antigen is a strong predictor of future prostate growth in men with benign prostatic hyperplasia. PROSCAR long-term efficacy and safety study. J Urol 2000, 163:13-20.
5. Roehrborn CG, Boyle P, Gould AL, Waldstreicher J: Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia. Urology 1999, 53:581-589.
6. Mochtar CA, Kiemeney LA, van Riemsdijk MM, et al.: Prostate-specific antigen as an estimator of prostate volume in the management of patients with symptomatic benign prostatic hyperplasia. Eur Urol 2003, 44:695-700.
7. Chung BH, Hong SJ, Cho JS, Seong DH: Relationship between serum prostate-specific antigen and prostate volume in Korean men with benign prostatic hyperplasia: a multicentre study. BJU Int 2006, 97:742-746.
8. Roehrborn CG, Malice M, Cook TJ, Girman CJ: Clinical predictors of spontaneous acute urinary retention in men with LUTS and clinical BPH: a comprehensive analysis of the pooled placebo groups of several large clinical trials. Urology 2001, 58:210-216.
9. Roehrborn CG, McConnell JD, Lieber M, et al.: Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. PLESS Study Group. Urology 1999, 53:473-480.
10. Wang MC, Valenzuela LA, Murphy GP, Chu TM: Purification of a human prostate specific antigen. Invest Urol 1979, 17:159-163.
11. Catalona WJ, Smith DS, Ratliff TL, et al.: Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991, 324:1156-1161.
12. Stamey TA, Yang N, Hay AR, et al.: Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987, 317:909-916.
13. Diamandis EP: Prostate specific antigen: new applications in breast and other cancers. Anticancer Res 1996, 16:3983-3984.
14. Robert M, Gibbs BF, Jacobson E, Gagnon C: Characterization of prostate-specific antigen proteolytic activity on its major physiological substrate, the sperm motility inhibitor precursor/semenogelin I. Biochemistry 1997, 36:3811-3819.
15. Borgono CA, Michael IP, Diamandis EP: Human tissue kallikreins: physiologic roles and applications in cancer. Mol Cancer Res 2004, 2:257-280.
16. Lundwall A, Lilja H: Molecular cloning of human prostate specific antigen cDNA. FEBS Lett 1987, 214:317-322.
17. Kumar A, Mikolajczyk SD, Goel AS, et al.: Expression of pro form of prostate-specific antigen by mammalian cells and its conversion to mature, active form by human kallikrein 2. Cancer Res 1997, 57:3111-3114.
18. Lilja H: Biology of prostate-specific antigen. Urology 2003, 62:27-33.
19. Villoutreix BO, Getzoff ED, Griffin JH: A structural model for the prostate disease marker, human prostate-specific antigen. Protein Sci 1994, 3:2033-2044.
20. Christensson A Lilja H: Complex formation between protein C inhibitor and prostate-specific antigen in vitro and in human semen. Eur J Biochem 1994, 220:45-53.
21. Stenman UH, Leinonen J, Alfthan H, et al.: A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res 1991, 51:222-226.
22. Woodrum DL, Brawer MK, Partin AW, et al.: Interpretation of free prostate specific antigen clinical research studies for the detection of prostate cancer. J Urol 1998, 159:5-12.
23. Catalona WJ, Smith DS, Wolfert RL, et al.: Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA 1995, 274:1214-1220.
24. Catalona WJ, Southwick PC, Slawin KM, et al.: Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging. Urology 2000, 56:255-260.
25. Haese A, Graefen M, Noldus J, Hammerer P, et al.: Prostatic volume and ratio of free-to-total prostate specific antigen in patients with prostatic cancer or benign prostatic hyperplasia. J Urol 1997, 158:2188-2192.
26. Mettlin C, Chesley AE, Murphy GP, et al.: Association of free PSA percent, total PSA, age, and gland volume in the detection of prostate cancer. Prostate 1999, 39:153-158.
27. Stephan C, Lein M, Jung K, et al.: The influence of prostate volume on the ratio of free to total prostate specific antigen in serum of patients with prostate carcinoma and benign prostate hyperplasia. Cancer 1997, 79:104-109.
28. Morote J, Encabo G, Lopez M, de Torres IM: Prediction of prostate volume based on total and free serum prostate-specific antigen: is it reliable? Eur Urol 2000, 38:91-95.
29. Canto EI, Singh H, Shariat SF, et al.: Serum BPSA outperforms both total PSA and free PSA as a predictor of prostatic enlargement in men without prostate cancer. Urology 2004, 63:905-910. This was the first report demonstrating that serum levels of BPSA (now renamed BPH-A) had an age-independent association with prostate volume in men with BPH.
30. Mikolajczyk SD, Grauer LS, Millar LS, et al.: A precursor form of PSA (pPSA) is a component of the free PSA in prostate cancer serum. Urology 1997, 50:710-714.
31. Peter JC, Unverzagt TN, Krogh O, et al.: Identification of precursor forms of free prostate-specific antigen in serum of prostate cancer patients by immunosorption and mass spectrometry. Cancer Res 2001, 61:957-962.
32. de Vries SH, Raaijmakers R, Blijenberg BG, et al.: Additional use of [-2] precursor prostate-specific antigen and "benign" PSA at diagnosis in screen-detected prostate cancer. Urology 2005, 65:926-930.
33. Niemela P, Lovgren J, Karp M, et al.: Sensitive and specific enzymatic assay for the determination of precursor forms of prostate-specific antigen after an activation step. Clin Chem 2002, 48:1257-1264.
34. Mikolajczyk SD, Marker KM, Millar LS, et al.: A truncated precursor form of prostate-specific antigen is a more specific serum marker of prostate cancer. Cancer Res 2001, 61:6958-6963.
35. Chan TY, Mikolajczyk SD, Lecksell K, et al.: Immunohistochemical staining of prostate cancer with monoclonal antibodies to the precursor of prostate-specific antigen. Urology 2003, 62:177-181.
36. Catalona WJ, Bartsch G, Rittenhouse HG, et al.: Serum pro prostate specific antigen improves cancer detection compared to free and complexed prostate specific antigen in men with prostate specific antigen 2 to 4 ng/ml. J Urol 2003, 170:2181-2185.
37. Sokoll LJ, Chan DW, Mikolajczyk SD, et al.: Proenzyme psa for the early detection of prostate cancer in the 2.5-4.0 ng/ml total psa range: preliminary analysis. Urology 2003, 61:274-276.
38. Khan MA, Sokoll LJ, Chan DW, et al.: Clinical utility of proPSA and "benign" PSA when percent free PSA is less than 15%. Urology 2004, 64:1160-1164.
39. Naya Y, Fritsche HA, Bhadkamkar VA, et al.: Volume-based evaluation of serum assays for new prostate-specific antigen isoforms in the detection of prostate cancer. Urology 2004, 63:492-498.
40. Bangma CH, Wildhagen MF, Yurdakul G, et al.: The value of (-7, -5)pro-prostate-specific antigen and human kallikrein-2 as serum markers for grading prostate cancer. BJU Int 2004, 93:720-724.
41. Naya Y, Fritsche HA, Bhadkamkar VA, et al.: Evaluation of precursor prostate-specific antigen isoform ratios in the detection of prostate cancer. Urol Oncol 2005, 23:16-21.
42. Mikolajczyk SD, Millar LS, Wang TJ, et al.: "BPSA," a specific molecular form of free prostate-specific antigen, is found predominantly in the transition zone of patients with nodular benign prostatic hyperplasia. Urology 2000, 55:41-45.
43. Mikolajczyk SD, Millar LS, Marker KM, et al.: Seminal plasma contains "BPSA," a molecular form of prostate-specific antigen that is associated with benign prostatic hyperplasia. Prostate 2000, 45:271-276.
44. Linton HJ, Marks LS, Millar LS, et al.: Benign prostate-specific antigen (BPSA) in serum is increased in benign prostate disease. Clin Chem 2003, 49:253-259.